Oncolytic Virotherapy with Myxoma Virus and Myxomaviral Immune Modulating Serpin - a New Class of Virus-derived Therapeutic

Start Date & Time: 
Friday, 21 July, 2017 - 16:00
End Date & Time: 
Friday, 21 July, 2017 - 17:00
Venue: 

Amphitheatre
Level 2
Duke-NUS Medical School
8 College Road
Singapore 169857

Speaker: 
Speaker Details: 

Dr Grant McFadden, Professor, Arizona State University
Director of the Biodesign Center for Immunotherapy, 
Vaccines and Virotherapy (B-CIVV)

Speaker: 
Speaker Details: 

Dr Alexandra Lucas, MSc, MD, FRCP(C)
Professor at the Biodesign Institute in Arizona State University and 
Director of Cardiovascular Fellowship Research at St Joseph’s Medical Center

Synopsis: 

Oncolytic Virotherapy with Myxoma Virus

The McFadden lab studies how poxviruses that cause immunosuppression interact with the host immune system, with specific focus on virus tropism, virus-encoded immune inhibitors, and the deployment of specific poxviruses for oncolytic virotherapy to treat cancer. He is also currently developing human clinical trials to exploit virotherapy with one specific poxvirus, myxoma virus, to improve hematopoietic stem cell transplantation therapies for cancer.

Myxomaviral Immune Modulating Serpin  - a New Class of Virus-derived Therapeutic

The Lucas lab studies Inflammatory vascular syndromes (IVS) and transplant vascular disease, both devastating disorders. Mouse Herpesviral (MHV68) infection is a model for a lethal IVS. The Lucas lab has developed a Myxomavirus-derived Serp-1 protein and reactive center peptides as first in class therapeutics for vascular inflammation, reducing markers of heart damage in a clinical trial and improving survival in MHV68 IVS. The roles of inflammation and the gut microbiome are now under investigation in MHV68 infection with serpin treatment, as a new focus for treatment in IVS.

Biography: 

Grant McFadden is currently a Professor at Arizona State University and is the new Director of the Biodesign Center for Immunotherapy, Vaccines and Virotherapy (B-CIVV). He is the co-Editor-in-Chief of the Open Access journal PLoS Pathogens, a Senior Editor at Journal of Virology (ASM Press), and he is the outgoing President of the American Society for Virology (2015-16). His lab investigates host-virus tropism, and the deployment of poxviruses for oncolytic virotherapy for the treatment of cancer, particularly with myxoma virus (MYXV). To date, McFadden has published over 340 scientific papers and reviews. 

Alexandra Lucas is a professor with 27 years experience in vascular research. Dr. Lucas has worked in universities in Canada and the US developing research initiatives in inflammatory vascular disease, sepsis and transplant rejection. Dr Lucas has over 130 papers and reviews, with funding from national agencies in Canada and the US. She has developed virus-derived anti-inflammatory proteins as a first-in-class family of biologic therapeutics, taking these agents from bench to bedside and 20 patents filed. Her work was instrumental in taking one protein from preclinical to a successful Phase 2A clinical trial. Dr. Lucas is a Professor at the Biodesign Institute in Arizona State University and Director of Cardiovascular Fellowship Research at St Joseph’s Medical Center.

Host: 

Linfa Wang
Professor and Director
Programme in Emerging Infectious Diseases

 

Contact Person: 

Shirley William
shirleywilliam@duke-nus.edu.sg